 |
|
|
| |
Next generation core inhibitors ABI-H3733 and ABI-4334 have significantly improved potency and target WED-114 coverage for both antiviral and cccDNA formation activities compared to first-generation core inhibitors
|
| |
| |
EASL 2023 June 21-24 Vienna
Nuruddin Unchwaniwala, Katie Zomorodi, Michael Shen, Ran Yan, Ariel Tang, Xiang Xu, Michel Perron, William Delaney, Kathryn M. Kitrinos
Assembly Biosciences, Inc., South San Francisco, CA, USA
|
| |
|
|
|
|
|
